Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
Year: 2022
Type: article
Source: Blood
Authors: Alexander Roeth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M.I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Jennifer Wang, Deepthi Vagge, Marek Wardecki, Frank Shafer, Michelle Lee, Catherine M. Broome
Institutions: Essen University Hospital, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University College London Hospitals NHS Foundation Trust, Medical University of Vienna, Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, University of Southern California, Ishikawa Prefectural Central Hospital, The University of Osaka, Amsterdam University Medical Centers, University of Amsterdam, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Sanofi (United States), MedStar Georgetown University Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4310106136